The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...

CWA Asset Management Group LLC trimmed its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) ...

which showed that treatment with once-daily Alyftrek enhanced patient benefit compared to Vertex’s blockbuster CF drug Trikafta (Kaftrio in Europe), which is required to be administered twice daily.

Trikafta—known as Kaftrio in Europe—itself has contributed $7.5 billion during the first nine months of 2024. But investors’ attention has lately shifted to suzetrigine, a nonaddictive pain ...

Nordea Investment Management AB increased its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 19.4% during the fourth quarter, Holdings Channel reports. The ...

The approval is based on data from a comprehensive late-stage program, which showed that treatment with once-daily Alyftrek enhanced patient benefit compared to Vertex’s blockbuster CF drug Trikafta ...

T-Mobile, Toyota Motor, Vertex Pharmaceuticals, BK Technologies and Servotronics are part of the Zacks top Analyst Blog.

Vertex’s CF sales continue to grow, driven by its triple therapy, Trikafta/Kaftrio, in younger age groups. While in the near term, expansion to younger age groups should continue to drive CF ...

Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through ...